Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Neuraceq
Florbetaben F 18 is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to detect the presence of amyloid plaques in the brain, a hallmark of Alzheimer's disease. It binds specifically to beta-amyloid plaques, allowing for visualization and quantification of amyloid deposition. This information aids in the diagnosis of Alzheimer's disease and helps differentiate it from other forms of dementia.
Used for the detection of amyloid plaques in the brain in patients being evaluated for Alzheimer's disease and other causes of cognitive decline.
Outcome:
Potential harm to the fetus
Mechanism:
Radiation exposure
Outcome:
Potential for misinterpretation of florbetaben PET scan
Mechanism:
Florbetaben can bind to amyloid in blood vessels, mimicking amyloid plaques.
Outcome:
Potential for reduced florbetaben uptake
Mechanism:
Competition for amyloid binding sites
Most likely new formulation: Improved sensitivity and specificity for earlier detection of amyloid plaques (2025, 70% confidence)
Based on current usage patterns and clinical trial data, there is a high likelihood (>90%) that florbetaben F 18 will remain a valuable diagnostic tool for Alzheimer's disease.
Radiopharmaceutical, Diagnostic Agent
Benzothiazole